USPSTF recommends clinicians prescribe Statins for the primary CVD prevention in adults (40-75 yrs) w/ 1 or more CVD risk factors (ie, dyslipidemia, DM, HTN, smoking) & 10-year CVD risk of 10% or greater. Inflammatory dz is considered a CV risk enhancer https://t.co/1Opblbiz7B https://t.co/xSw2uPUoKK

Review of steroids & immunosuppressants on cancer outcomes in checkpoint inhibitor therapy - Steroid use "for irAEs may not have a large deleterious effect on overall survival" - DMARDs for irAE "a major drawback in the delay in the onset of response" https://t.co/8o8JBMpqML https://t.co/bWuLT3zYPm

MIRROR study lead to pegloticase (PEG) label change - adding MTX as Rx to reduced anti-PEG Abs. Based on 14 refractory gout pts given MTX 15mg/wk (w/ folate) and then PEG IV: 3 nonresponders, 1 dropped out, 10 responded/stayed on Rx x 52 wks w/ less ADAbs https://t.co/BZwY7DpmIb https://t.co/gNhhuhmTG5

Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow. https://t.co/ZaWnjxiR3W https://t.co/8CElIxWk1v https://t.co/ZVayc3Qt1r

EULAR/ACR Classification in MDA5+ Myositis Patients A current analysis suggests that nearly 30% of MDA5 IIM patients may be missed by the 2017 EULAR/ACR classification criteria for IIM. https://t.co/rS25rL5fGO https://t.co/Yw7sGmPW5G

Drugs causing Scleroderma (DASSc) - Anticancer rx made up 42% DASSc & 62.3% case reports. Included: taxane-based agents, bleomycin, vinblastine, imatinib, dacarbazine, pembrolizumab pemetrexed; also HRT romiplostim & eculizumab https://t.co/szQmNPO0eu https://t.co/z4tdP4I1kc

A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO Sponsored by Lilly USA Listen to Philip Mease and April Armstrong discuss a multidisciplinary approach and importantconsiderations when treating patients with joint and skin concerns. https://t.co/lTfz2kUr51 https://t.co/jVp8Uk0uH5

Longitudinal study of 411 adult fibromyalgia pts showed that 73.2% had depression at enrollment. Higher depression scores at baseline predicted poorer functional outcomes. Effectively treated depression resulted in improved functioning at follow-up. https://t.co/D43r4Z5llU https://t.co/a9EgyJLHza

Head Scratcher? Study of UK Biobank cohort (n=380,380) shows those taking Rx Folate had increased risk of COVID-19 Dx (OR 1.51; 1.42–1.61) and Death (OR 2.64; 2.15–3.24). MTX use (+/- folate) had no increase in COVID or COVID death(1.07;0.57–1.98) https://t.co/MLE1sL7KG2 https://t.co/adoLO9qLON

FDA Approves BA.4 and BA.5 Omicron COVID Booster Vaccines Today the FDA authorized the updated Omicron subvariant (BA.4 and BA.5) COVID-19 booster shots manufactured by Pfizer and Moderna; with an anticipated ship/start date of early September 2022. https://t.co/VzQBFgvAqu https://t.co/r0pQuoDVcn

Study of 497 pts referred by general practitioners to rheumatologist (2018-19) showed: - GP Dx changed by Rheum in 58% - Low complexity Dx (FM, OA) acct for 50% referrals - 46% of referrals inappropriate - GP correlations w/ Rheum Dx poor (κ < 0.5) https://t.co/q592iHQZbq https://t.co/XyPdtpHQGK

Recent review of AOSD suggests: - AOSD & SJIA are the same - Classify dz as systemic or articular - #MAS occurs in up to 23% - Yamaguchi & Fautrel criteria are widely used - Cytokines important: IL-1, IL-6, IL-18, IL-37 - only Canakinumab is FDA-approved https://t.co/4ERA56Wqcb https://t.co/FkIWxIrwxX